Multiple myeloma (MM) is a plasma cell (PC) malignancy of terminally differentiated B lymphocytes that is typically associated with the secretion of partial and/or complete monoclonal immunoglobulins and a constellation of particular symptoms and signs. MM is a treatable condition and timely diagnosis is essential to limit or avoid irreversible target-organ damage and to prolong survival.
I N T E R P R E T A T I O N A N D U S E
When interpreting the recommendations, clinicians should bear in mind that each recommendation is based on clinical evidence, as well as clinical experience and knowledge gained through daily practice as well as national and international collaboration with experts in the field of MM. Although the recommendations are intended to be a flexible tool to assist with timely and informed decisions, they should not replace sound clinical judgment or be used as a legal resource.
S P E C T R U M O F P L A S M A C E L L N E O P L A S M S
Overview MM evolves from a clinically silent state termed monoclonal gammopathy of undetermined significance (MGUS). 7, 8 MGUS is a condition with low risk of conversion to overtly symptomatic disease requiring therapy (~1% per year). 9, 10 The risk of evolution to symptomatic disease rises with increasing clonal PC burden and is defined as smouldering MM (SMM), an intermediate stage associated with a higher risk of progression to overt MM (~10% per year). 9, 11 Both MGUS and SMM are, by definition, asymptomatic and are differentiated by the amount of secreted monoclonal protein (M-protein) and/or the extent of clonal PC involvement on bone marrow examination. 6 The IMWG diagnostic criteria for MGUS and related plasma-cell disorders (Table 1) are primarily characterized by serum M-protein (IgM or non-IgM) < 30 g/L, urinary M-protein < 500 mg/24 hr, clonal bone marrow PCs (BMPCs) < 10%, and a lack of end-organ damage, as per CRAB criteria. 6 The revised IMWG diagnostic criteria for SMM and MM are listed in Table 2 . Briefly, SMM is characterized by serum M-protein (IgG or IgA) ≥ 30 g/L or urinary M-protein ≥ 500 mg/24 hr, and/or 10% to 60% clonal BMPCs. 6 These criteria must be present in the absence of myeloma-defining events (MDEs) or light-chain (AL) amyloidosis. 6 Overt symptomatic MM is defined by the presence of a clonal PC population (BMPCs ≥ 10% or biopsy-proven extramedullary plasmacytoma) with any one of the following MDEs: 1) end-organ damage attributed to an underlying PC proliferative disorder, as per CRAB criteria; 2) ≥ 1 biomarker of malignancy (clonal BMPC > 60%, involved:uninvolved serum free light chain ratio [sFLCr] ≥ 100, or > 1 focal lesion ≥ 5 mm on magnetic resonance imaging [MRI]). 6 An MM variant called plasma cell leukemia (PCL) is a very aggressive form of MM characterized by high levels of abnormal PCs circulating in the peripheral blood. 12 PCL is defined as the presence of PCs comprising ≥ 20% of the white blood cell (WBC) differential count or an absolute PC count greater than 2.0 x 10 9 cells/L in the peripheral blood. 13 PCL can be detected de novo without prior history of MM (primary PCL) or with a known history of MM (secondary PCL).
A recently described group of diseases called monoclonal gammopathy of clinical significance (MGCS) is usually associated with low clonal PC/lymphoplasmacytoid cell burden and involves various tissues, particularly the kidneys (monoclonal gammopathy of renal significance [MGRS] ). [14] [15] [16] They are associated with deposition/precipitation of secreted monoclonal immunoglobulins or their fragments, or immune dysfunction through auto-antibodies or complement activation. These disorders are associated with a great deal of morbidity, and even mortality, and their pathologic features should be distinguished from MGUS because treatment is required. [14] [15] [16] A detailed review of MGCS is beyond the scope of this document; however, if MGCS is suspected, confirmation of pathological monoclonal immunoglobulin deposition in the affected tissue is often required. It is also important to exclude a chance association, especially in the elderly, as there is a relatively high prevalence of monoclonal gammopathy in this population. 17 Other disorders associated with PC neoplasms include solitary plasmacytoma, 18 AL amyloidosis, 19 POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, and Skin changes) syndrome, 19 or other MGCS. [14] [15] [16] In amyloidosis and POEMS syndrome, the current understanding is that clonal PCs synthesize immunoglobulin light chain or heavy chain fragments that cannot be completely broken down to their constituent amino acids. 19 In AL amyloidosis, target organ dysfunction is the result of misfolded immunoglobulin light chain fragments that are deposited in tissues. 19 Solitary plasmacytomas, localized proliferation of neoplastic monoclonal PCs, are an uncommon type of PC neoplasm that account for approximately 2% to 5% of all PC disorders. 18 There are two types of solitary plasmacytomas: 1) medullary plasmacytoma arising from the marrow and 2) extramedullary plasmacytomas originating from soft tissues. 18, 20 Both are characterized by no radiologic evidence of additional skeletal lesions, absence of signs and symptoms of MM, and bone marrow examinations that are morphologically normal or with very low clonal PC infiltrations (< 10%). 6, 18 Although solitary plasmacytomas with ≥ 10% clonal PCs may be regarded as MM, 6 the majority of patients with extramedullary plasmacytoma have localized disease that are potentially curable with irradiation. 21 It is important to recognize, however, that a majority of patients with medullary plasmacytoma eventually progress to overt MM. 22 Thus, these patients require close follow-up and monitoring.
The focus of this document is on the spectrum of PC neoplasms ranging from MGUS to symptomatic MM.
Clinical Presentation of MM
Due to the non-specific nature of presenting symptoms, the early detection of MM in the primary care setting is challenging. The most common presenting signs and symptoms include bone pain and lytic lesions (including pathologic fractures), anemia, fatigue, infections, weight loss, hypercalcemia, and renal dysfunction. 6, 23, 24 Bone pain is the most common symptom at presentation, with the lumbar spine being one of the most frequent sites of pain. The vast majority of patients have more than one site of bony involvement. 25, 26 Often, the diagnosis is suggested by a radiologist who identifies evidence of lytic lesions upon review of radiographs ordered for bony pain or other reasons. Anemia is usually normochromic normocytic, and hypercalcemia can lead to additional presenting symptoms such as confusion, somnolence, constipation, nausea, and thirst. Important consideration should be given to the differential diagnosis of MM -manifestations that may be initially attributed to another disease process. These may include back pain attributed to degenerative spine issues, anemia and renal failure attributed to other systemic comorbidities, bone pain attributed to polymyalgia rheumatica, or bone lesions and hypercalcemia attributed to metastatic cancer of another origin. Conversely, metastatic carcinoma of bone and combinations of conditions that mimic CRAB (hypercalcemia of other origin [eg, hyperparathyroidism], renal failure of other origin [eg, diabetes, vascular disease], anemia of other origin, and diffuse severe osteoporosis with imaging findings mimicking diffuse osteolysis of MM) are often misdiagnosed as MM.
Less common presentations of MM are: 1) plasmacytoma(s); 22, 27 2) neurologic symptoms, such as peripheral neuropathy (including paresthesia and sensory loss) and carpal tunnel syndrome (due to coexistent primary AL amyloidosis); 28, 29 3) recurrent or atypical infection; 30,31 4) features of systemic primary AL amyloidosis, which can manifest as any or all of gastrointestinal symptoms, cardiomyopathy, peripheral neuropathy, organomegaly, or skin infiltration; 29 and 5) hyperviscosity with non-specific features, including malaise, headache, and change in mentation. This latter presentation is much more common, however, in Waldenström macroglobulinemia (10%-30%) than in MM (2%-6%) and more common in MMs that secrete IgA rather than those secreting IgG monoclonal proteins. 32 Physical examination findings across the spectrum of PC neoplasms are broad; therefore, we recommend that the first step in diagnosing suspected PC neoplasms is a complete physical and neurological examination, with a focus on areas of pain to detect bone fractures, spinal cord compression and potential plasmacytoma(s) affecting critical structures. Neurologic examinations are useful to diagnose cord or peripheral nerve compressions. Rule out amyloidosis and POEMS syndrome, and conduct a careful analysis of past medical history, including history of recurrent atypical infections.
D I A G N O S I N G A N D M O N I T O R I N G O F M G U S A N D S M M

MGUS
The incidence of MGUS increases with age, 33 presenting in approximately 3% of the general population over the age of 50. 34 MGUS is characterized by the presence of a clonal population of PCs that is not associated with any clinical disease. The IMWG defines this as serum M-protein < 30 g/L, urinary monoclonal protein < 500 mg/24h, clonal BMPCs < 10%, and an absence of CRAB features (Table 1) . 6 Three distinct clinical types of MGUS have been identified: 1) immunoglobulin M (IgM) MGUS; 2) non-IgM MGUS (ie, producing mostly IgG or IgA); and 3) free light chain only MGUS. Identification of clinical MGUS type is an important component of risk stratification (Tables 3  and 4 ) and can be helpful for patient counselling and management. 35, 36 MGUS type also provides information on annual rate of transformation and potential type/pattern of progression to distinct plasma cell disorders. 37 Notably, the presence of non-IgG MGUS (excluding light chain MGUS) is a risk factor for progression to MM or related disorders.
It is important to recognize that MGUS is a diagnosis of exclusion; therefore, the primary goal in the diagnostic workup for MGUS involves ruling out other disorders. The next goal is patient stratification based on risk of progression to guide monitoring. In order to reflect the realities of the Canadian healthcare landscape, the MCRN-CGC recommendations on the diagnosis and monitoring of MGUS differ from the IMWG recommendations. 6, 38 Once a monoclonal gammopathy is documented, diagnostic workup should begin with basic bloodwork to identify the serologic criteria for hypercalcemia, renal impairment, and anemia. Based on risk stratification, we recommend whole-body low-dose computed tomography (WBLDCT) in MGUS patients with > 1 risk factor present. If WBLDCT is not available, skeletal survey by conventional radiography or whole-body MRI are acceptable alternatives. Bone imaging in IgM MGUS is typically not useful or recommended. [37] [38] If findings are negative, there is no need to repeat imaging, unless medically indicated. If findings are clearly positive, action should be taken accordingly. If the findings are equivocal, consider MRI or 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) to add further clarity to the nature of the lesions observed. Further consideration should also be given for imaging if there is a clinical suspicion of either a higher burden of disease or based on symptomatology. Such imaging may include skeletal survey by conventional radiography, WBLDCT, MRI, or 18F-FDG-PET/CT to better characterize disease burden.
The rate of reclassification of MGUS to MM based on detection of bone lesions or plasmacytomas by advanced imaging is low (less than 5%). [39] [40] While WBLDCT and MRI have similar sensitivity in detecting bony lesions in the chest, pelvis, humeri and femori, MRI is superior for detecting extramedullary and spinal lesions, and WBLDCT is more sensitive for detecting osteolytic lesions in the skull. [39] [40] Bone marrow examination should be considered in intermediate-to high-risk patients when results may have an impact on diagnosis, long-term management and/or therapy. At the time of biopsy and aspiration, a bone marrow sample should be drawn for cytogenetic testing with fluorescence in situ hybridization (FISH); however, the diagnostic test should only be processed if the bone marrow PC (BMPC) count is ≥ 10% and/or the diagnosis of MM has been clearly established. Additional testing may be required in select patients to rule out other diseases or PC disorders. Such tests can include, but are not limited to, lactate dehydrogenase (LDH), beta-2 microglobulin (β2M), B-type natriuretic peptide (BNP), or N-terminal pro-BNP (NT-pro-BNP).
The purpose of MGUS follow-up is to detect early transformation in order to initiate timely treatment, minimize major complications and prolong survival. 37 Given the seriousness of certain complications and the relative ease with which testing for M-proteins can be added to other routine medical tests, regular follow-up is recommended for the vast majority of MGUS patients. Baseline investigations should be repeated in all patients at 6 months. If findings remain stable, most patients can be followed-up annually thereafter. More frequent monitoring may be indicated in intermediate-to high-risk patients, particularly if there is evidence of disease progression. 34, 41 Low-risk patients do not necessarily require monitoring with bone marrow biopsy or skeletal survey, except if confounding factors are recognized.
While the greatest focus is put on the progression of MGUS to MM, it is important to remain mindful of the risk of development or co-presentation of a gammopathy related condition (ie, AL amyloidosis, MGRS and other MGCS). As such, screening serologic investigations should include examining for unexplained albuminuria (including protein/creatinine ratio), with more detailed investigations determined by a patient's given clinical presentation. 42 Due to the risk of cardiac AL amyloidosis in light-chain MGUS, baseline investigation should also examine for elevated cardiac biomarkers (ie, BNP, NT-pro-BNP, or highly sensitive troponin [hsTrop] T/L depending on availability). 43, 44 If found to be elevated, prompt referral to hematology is recommended to guide workup.
There is clear epidemiologic evidence that individuals with MGUS are at increased risk of bone fracture independent of the development of overt MM and that the prevalence of osteopenia/osteoporosis is increased in those with MGUS as compared to age and sex matched controls without MGUS. 33, 45 Thus, MGUS patients, especially those with other risk factors for osteoporosis, should be assessed for bone loss by dual energy X-ray absorptiometry (DXA). 46 
SMM
SMM is characterized by higher clonal PC burden than MGUS with 10% to 60% clonal BMPCs and/or a serum Mprotein ≥ 30 g/L, a urinary monoclonal protein ≥ 500 mg/24h, but an absence of any CRAB features ( Table 2) . Unlike MGUS, SMM is a relatively uncommon clinical entity. 49 While the majority of patients with MM have been found to have pre-existing MGUS, 8 according to the Swedish Myeloma Registry, only 19% of MM patients were classified as having a preceding diagnosis of SMM. 50 Since SMM is asymptomatic, newly-diagnosed patients are typically detected when elevated M-proteins are discovered incidentally on laboratory testing as part of the workup for other disorders. 33, 51 Due to the higher rate of transformation of SMM to MM (versus MGUS to SMM), patients with SMM spend less time in this state and come to clinical attention only once symptoms become apparent.
In SMM, the risk of progression to malignancy is the highest (10% per year) for the first 5 years, then decreases to 3% per year for the next 5 years and to 1% per year thereafter. 8 In fact, 50% of patients with newly-diagnosed SMM progress within the first 5 years. On the other hand, approximately one-third of patients with newly-diagnosed SMM will not progress in the first 10 years after diagnosis. These patients may have disease biology similar to MGUS, yet with more clonal BMPCs or a higher M-protein count than that specified in the clinical definition of MGUS. Risk stratification models may help distinguish between these two classes of SMM patients.
A diagnostic workup for SMM should include a complete blood count (CBC), WBC differential count, peripheral blood smear, serum calcium with albumin, creatinine clearance (and/or serum creatinine), total serum protein, serum protein electrophoresis (SPEP) with serum immunofixation electrophoresis (IFE), sFLC assay, 24-hour total urine protein with electrophoresis (UPEP) and IFE, quantitative immunoglobulins (IgA, IgG, IgM), and bone marrow examination with FISH for detection of high-risk cytogenetics (although earlier intervention is not indicated if highrisk FISH results are noted). Patients should also undergo general assessments of hepatic and renal parameters.
Additional tests that may be appropriate, based on risk stratification and clinical presentation, include LDH, β2M, BNP, or NT-proBNP. These can help rule out other disorders, including other PC disorders as with the MGUS workup above.
To exclude osteolytic lesions, we recommend that all patients undergo WBLDCT. If WBLDCT is unavailable, skeletal survey by conventional radiography or whole-body MRI are acceptable alternatives. If WBLDCT is unavailable or if results are negative or equivocal, 18F-FDG-PET/CT whole-body MRI (or MRI of the spine and pelvis, if whole-body MRI is not available) is required to exclude focal lesions as MDEs. When performing an MRI of the spine and pelvis, clinicians should note that 10% of lesions might be missed.
Two prognostic models for SMM have been well studied in prospective trials: the Mayo Clinic model 9 and the model proposed by the Spanish Myeloma Group. 52 More recently in 2018, a model that incorporates the revised IMWG diagnostic criteria was proposed by Lakshman et al. 53 The Mayo Clinic model uses the quantity of the serum M-protein and extent of bone marrow involvement. These variables classify SMM into three risk groups: 1) serum M-protein ≥ 30 g/L and ≥ 10% clonal BMPCs; 2) M-protein < 30 g/L and ≥ 10% clonal BMPCs; and 3) M-protein ≥ 30 g/L and clonal BMPCs < 10%. The median time to progression (TTP) to MM is significantly different among the 3 groups, at 2, 8 and 19 years, respectively. 9 The probability of progression at 15 years is 87%, 70%, and 39%, respectively.
The model developed by the Spanish Myeloma Group utilizes the presence of 2 risk factors in patients with SMM who have ≥ 10% clonal BMPCs: 1) presence of an aberrant PC immunophenotype in > 95% of clonal PCs; and 2) immunoparesis (reduction in ≥ 1 uninvolved immunoglobulin by > 25% compared to normal). 52 Patients with both risk factors have a median TTP of 23 months, compared with 73 months when only 1 risk factor is present. 52 TTP is not calculated when neither risk factor is present. The Spanish model is, however, not easily applicable to Canadian practice, as many centres do not use the next generation flow cytometry technique used by the Spanish to detect an aberrant PC immunophenotype.
The third model takes 3 risk factors into account: 1) BMPCs > 20%; 2) sFLCr > 20; and 3) M-protein > 20 g/L. 53 The risk stratification system is based on the presence of no (low), 1 (intermediate), and ≥ 2 (high) risk factors. Median TTP was 110, 68 and 29 months, respectively (P < 0.0001). 53 All three of these models enable initial risk stratification of SMM. The risk stratification can then be further refined using additional prognostic factors. For example, the prognostic value of the initial Mayo Clinic model can be improved by adding sFLCr as a variable. 54 Evidence-based consensus on how frequently to follow-up patients with SMM is lacking. As a result, our follow-up recommendations are based on the best evidence of the likelihood of progression and the presence of risk factors.
As the classification of high-risk SMM is of particular relevance for further follow-up and therapeutic approaches, it should be based on all available data on a given patient rather than a restricted set of variables. Revised criteria for high-risk SMM that incorporate both the Mayo Clinic and Spanish Myeloma Group criteria, as well as other risk factors are listed in Table 5 . 49 Patients defined as having high-risk SMM should be followed closely and re-evaluated 2 to 3 months after the initial diagnosis. 55 If findings are stable, testing should be repeated every 4 to 6 months for 5 years and, if they continue to be stable, the period between evaluations can be lengthened to every 6 months. Patients with low-risk SMM should be seen every 3 to 4 months for the first year, followed by every 6 months, if clinically stable, for life or until progression. 55 Patients with SMM do not require repeat imaging, but it should be performed if clinically indicated. 49, 56 In patients with baseline MRI abnormalities, an increase in the number and/or size of lesions has diagnostic and prognostic value. 57 Therefore, in patients with MRI showing a solitary focal lesion, diffuse infiltration, or equivocal findings, follow-up examination is recommended in 3 to 6 months. 6 
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Diagnosing SMM
Baseline investigation: CBC, WBC differential count, peripheral blood smear, serum calcium with albumin, creatinine clearance (and/or serum creatinine), total serum protein, SPEP with IFE, sFLC assay, 24-hour total urine protein with UPEP and IFE, quantitative immunoglobulins (IgA, IgG, IgM), and bone marrow examination with FISH for detection of high-risk cytogenetics, in addition to general assessments of hepatic and renal parameters.
Based on risk stratification ( 
D I A G N O S I N G M U L T I P L E M Y E L O M A
Initial Laboratory Investigation
Overview
The initial laboratory investigation for MM should include CBC to assess for anemia, thrombocytopenia, or leukopenia. In the case of anemia, the reticulocyte count in MM is typically low and, by definition, no alternative cause should be present. Peripheral blood smears may show rouleaux formation (red cells taking on appearance of a stack of coins) due to elevated total serum protein and/or circulating PCs.
Serum analysis should include quantitative immunoglobulin levels (IgG, IgA and IgM), SPEP, IFE, as well as sFLC assay with kappa (κ) to lambda (λ) ratio to obtain specific information about the type(s) and quantities of Mprotein present. Urinalysis for initial workup should include a 24-hour urine for total protein and UPEP, which remains a part of the IMWG criteria for the diagnosis of PC disorders, and can provide valuable informationparticularly in patients with light-chain only disease. Additionally, UPEP is also used to examine for features indicative of related renal diseases falling in the category of MGRS. [15] [16] 58 Of particular importance is the presence of albuminuria that might indicate glomerular disease, a feature of AL amyloidosis and other conditions falling under the MGRS umbrella.
A baseline metabolic panel should be performed to assess coagulation factors, renal and liver function, as well as levels of serum calcium, total serum protein, albumin, beta-2 microglobulin (β2M), LDH, and blood glucose.
Although not required, assessment of uric acid can provide additional information, such as high cell turnover or dehydration.
Glucose Testing
Corticosteroids can cause blood glucose levels to rise, lead to diabetes, and complicate disease management. 59 Baseline blood glucose levels should be established prior to the initiation of treatment and monitored carefully during treatment.
Renal Function
As part of disease assessment and to guide treatment, renal function assessments should include creatinine clearance (and/or serum creatinine) and electrolytes (sodium, potassium, chloride, bicarbonate). Measured sodium levels in the blood may be decreased in the presence of a paraproteinemia. 60
Liver Function
Following the kidney, the liver is the second most common organ affected by light chains; however, the majority of MM patients remain asymptomatic or have only mild elevation of liver enzymes. 61 Liver dysfunction due to PC infiltration has been reported, however, and manifestations such as hepatomegaly, ascites, and jaundice are uncommon but possible. 61 MM presenting as jaundice has been reported due to hepatic amyloid deposition. 61 Liver function assessment should include bilirubin (total and direct), alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and prothrombin time (PT). ALP is often elevated in hepatic amyloidosis.
62
M-protein Assessment
Monoclonal immunoglobulins are markers of proliferative clonal PC diseases and have been described as the best serologic and urine-based tumour markers. 63 They vary in their molecular weight between 24,000 (FLC) and 900,000 (IgM) Daltons. 63 The unique structure of each M-protein makes them highly specific for each PC clone;
however, diverse disease presentations and the broad range of serum protein concentrations and molecular weights can pose some unique challenges. Thus, no single test can confidently diagnose or monitor all MM patients. 63 As single tests, sFLC, SPEP, and serum IFE can detect 74%, 79% and 87% of monoclonal immunoglobulins, respectively, and the three tests combined can detect 98.6% of monoclonal immunoglobulins. 63 Patients with light chain MM cannot be followed by SPEP alone due to the small size and low concentration of serum protein, unless concentrations reach more than 1000 mg/L. Serum FLC testing facilitates the identification and monitoring of these patients. Additional challenges are M-proteins that migrate in the β fraction(s) (ie, 30% of all IgAs may hide under the β fraction peak[s]). The broad peak often observed in such cases can be difficult to accurately quantify. While rarely posing a challenge in diagnosis, this can be problematic when following the peak over time as a marker of disease burden or response to treatment.
It should be noted that approximately 3% of MM patients have true non-secretory disease with no detectable Mprotein in the serum and urine. 25 On the other hand, M-protein may be present even when all fractions are within the reference intervals (may be hidden in other serum fractions on the gel). Thus, if MM is clinically suspected, IFE should be performed, even if SPEP appears normal, as the SPEP is a less sensitive test.
IFE permits the identification of proteins within complex mixtures after separation by conventional electrophoresis and is suitable for localization of discrete protein bands and diffuse zones. Uncomplexed antibodies and other proteins are washed and removed from the gel/membrane, leaving only the immunoprecipitates that are too large and insoluble. 64, 65 The remaining immunoprecipitates can then be identified by staining. IFE improves SPEP sensitivity by approximately 10-fold (from a limit of detection of 1.0 g/L [SPEP] to approximately 0. 
FLC Quantitation
Light chains are normally produced by PC in molar excess to heavy chains. The rapid turnover of FLC (2-6 hours) as compared with IgG (23 days) and other immunoglobulins (ie, IgA: 5.8 days, IgM: 5.1 days, IgD: 2.8 days, IgE: 2.3 days) contribute to FLC lability and thus make it a useful disease burden monitoring tool. 63 Quantitative FLC assays use antisera directed against epitopes that are exposed only when the light chains are free (unbound to heavy chain) in solution. Thus, FLC immunoassays can be used to specifically quantitate FLC even in the presence of large concentrations of normal serum immunoglobulins. The approach to diagnosis is to use the involved:uninvolved sFLCr to detect unbalanced light chain synthesis. Abnormal sFLC ratios have been detected in 90% to 95% of intact immunoglobulin MM and 40% of MGUS. 66 
Quantitative Total Immunoglobulin Testing
Quantitative immunoglobulin testing measures normal and monoclonal immunoglobulins. Its utility is largely in diagnosing concomitant hypogammaglobulinemia. It is also useful for monitoring monoclonal proteins that cannot be accurately quantified on SPEP such as IgAs that migrate to the β region of those gels.
Serum Viscosity
Increased serum viscosity usually results from increased circulating serum immunoglobulins. The signs of hyperviscosity syndrome include blurred or loss of vision, segmental dilation of retinal veins and flame-shaped hemorrhages, oronasal bleeding, headaches, vertigo, decreased hearing, ataxia, paresthesias, diplopia, somnolence, stupor, or coma. 67 Serum viscosity evaluation is recommended if IgM levels are > 40 g/L, IgA > 50 g/L, IgG > 60 g/L, or in symptomatic patients.
Relevance of β2M Level and LDH
β2M is a low molecular weight protein (11, 800 Daltons) synthesised by all nucleated cells and present in all bodily fluids. Its shares a structure similar to immunoglobulin molecules, with two β sheets linked by a disulfide bond and it associates with the alpha chain of class I major histocompatibility complex molecules, among other actions. β2M can accumulate in patients with renal dysfunction and can produce dialysis-related amyloidosis. Levels of β2M correlate with tumour burden in MM and fall with response to therapy. 68 It is a key feature of the International Staging System (ISS) 69 and the more recent revised ISS (R-ISS) 70 and thus, along with albumin and LDH, is an important baseline lab test in MM. Baseline LDH is also important for risk stratification, as part of the R-ISS and in itself may correlate with aggressive disease or PCL.
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We recommend the following minimally required baseline for laboratory investigation:
• CBC, WBC differential count, peripheral blood smear, serum calcium, total serum protein, albumin, β2M, and LDH and blood glucose • Creatinine clearance (and/or serum creatinine), electrolytes* and liver function tests** 
Bone Marrow Investigation
Bone Marrow Aspiration and Biopsy
Bone marrow aspiration and core biopsy are required for the quantification of PC and are necessary as part of the baseline workup for MM. PC quantification is expressed as the percentage of PC-to-total nucleated cells examined. Clonality is determined by in situ hybridization (ISH) for κ/λ mRNAs or less accurately with immunocytochemistry, on the core (trephine) biopsies or clot sections of the aspirate, if the former is not available. In addition to being another tool to determine clonality, flow cytometry can provide useful information with respect to aberrant immune profiles of the PC. 72 That said, it is not widely available and is not necessary for the diagnosis if a bone marrow biopsy is performed.
Chromosomal Aberrations and FISH
Myeloma cells typically divide at a low rate; therefore, standard cytogenetics are often unsuccessful and may reflect background hematopoiesis. Moreover, as many MM associated translocations in the PC fraction cannot be detected by standard G-banding karyotyping, other techniques have supplanted it and it is not a required test. Although chromosomal aberrations are not included in the diagnostic criteria for MM, cytogenetic evaluations by techniques such as FISH are required for all newly-diagnosed MM patients because they can provide important prognostic information, such as duration of remission and overall survival (OS). 73 In newly diagnosed MM, high-risk disease is minimally defined as the presence of at least one of the following chromosomal aberrations: del(17p), t(4;14)(p16;q32), or t(14;16)(q32;q23). A 2009 publication that compared high-risk vs standard risk cytogenetics showed that the presence of one of these aberrations results in an inferior OS (median OS of 24.5 months vs. 50.5 months). 74 Pending additional data, other adverse cytogenetic profiles that may confer high-risk include gain(1q) with R-ISS III, with or without del(1p), and t(14;20). [75] [76] Some of these genomic aberrations are included in the R-ISS for MM. 70 FISH targeted to the myeloma cells following either plasma cell staining or cell sorting is considered the standard technique for analysis of chromosomal aberrations in MM. A PC isolation step is integral to accurately capture aberrations found in the disease cell population. This greatly increases the sensitivity of detection and ensures that only MM-specific mutations are noted rather than germline anomalies potentially unrelated to the disease process. FISH testing includes t(4;14)(p16;q32), t(14;16)(q32;q23), del(17p13), and a marker for aneuploidy. FISH testing may also include gain(1q) and del(1p). Translocation t (11;14) results in upregulation of cyclinD1 and was identified as favorable in some studies, whereas it had no impact in others. [77] [78] [79] This translocation is associated with CD20 expression and lymphoplasmacytic morphology. In general, t(11;14), t(6;14), gain(5q), and hyperdiploidy do not confer poor prognosis.
Specific chromosomal aberrations identified in patients with MM involve deletions (del), translocations (t) and amplifications (gain
Other Techniques
FISH does not detect single-nucleotide variants (ie, in TP53 on chromosome 17p) that may influence prognosis and would only be detected by sequencing. [80] [81] Although standard karyotyping lacks the sensitivity to detect the important aberrations in PCs, it is highly sensitive for the detection of numerical chromosomal aberrations. For example, it is reliable for the detection of chromosome 13 aberrations, including interstitial deletion and monosomy. 82 Other promising techniques being used in research settings include single-nucleotide polymorphism, comparative genomic hybridization, and gene expression profiling; however, they are yet to be incorporated in clinical practice.
Cytogenetic Risk Stratification
Cytogenetic aberrations can be classified as primary or secondary -events that either contribute to PC immortalisation or disease progression, respectively. 83 The common primary and secondary cytogenetic aberrations in MM, MGUS, and SMM are listed in Table 6 . 84 The IMWG proposed a model where high-risk MM is defined as at least one of the following determined by FISH: del17p, t(4;14), or t(14;16). 74 The Mayo Clinic classification added hypodiploidy and t (14;20) to the definition of high-risk MM. 85 88 When attempting to stratify patients according to their prognostic risk based on cytogenetic analysis, it is important to keep in mind that while there are many single-centre studies and publications to provide some guidance, there is an overall lack of consensus. Currently, the stratification suggested by the IMWG is considered to be the gold standard and should be used to guide therapeutic decision-making. 
Imaging Investigation
Conventional radiography has been the gold standard for the detection of bone lesions in MM due to its widespread availability, low cost, and coverage of almost the entire skeletal system. However, it has low sensitivity, and lytic lesions are only detectable if > 30% of the bone cortex is destroyed. [89] [90] Furthermore, conventional radiography cannot detect or quantify diffuse bone marrow infiltration or extraosseous lesions. Despite these downfalls, skeletal survey remains an imaging option. However, the IMWG no longer recommends skeletal survey as the primary modality to determine the presence or absence of MM bone disease and, if available, newer imaging techniques are preferred. 38 In the past 10 years, advances have been made in imaging technology, and there has been more widespread use of MRI, WBLDCT (CT skeletal survey) and 18F-FDG-PET/CT for assessing lytic bone lesions and to detect early stages of bone marrow infiltration. Table 7 summarizes the pros and cons of the different imaging modalities in MM.
WBLDCT is increasingly used and is replacing conventional radiography at many centres. It has higher sensitivity for the detection of osseous lesions and has the capacity to detect extraosseous lesions. Based on a study by the IMWG, WBLDCT identifies significantly more sites of bone destruction than conventional skeletal survey. 91 Of 66
patients with SMM and a negative skeletal survey, 22.2% had lesions on WBLDCT. Based on these results, the investigators suggested WBLDCT as the preferred imaging technique for the detection of osteolytic lesions in MM; 38, 91 If available, we recommend performing WBLDCT as initial imaging for SMM. However, given that WBLDCT is not always available in the Canadian setting, skeletal survey is a reasonable alternative. If WBLDCT is unavailable or if initial imaging results are negative, 18F-FDG-PET/CT or whole-body MRI (or MRI of the spine and pelvis, if whole-body MRI is not available) is required to exclude focal lesions as MDEs.
As of 2014, MRI findings have been included in the IMWG diagnostic criteria. 6, 89 Compared with other radiographic methods, MRI has high sensitivity for the early detection of marrow infiltration by MM cells and can detect bone involvement in patients with MM prior to bone destruction, without radiation exposure. MRI is the gold standard for the imaging of the axial skeleton for the evaluation of back pain and for distinguishing benign versus malignant osteoporotic vertebral fractures. 89 MRI also has the ability to detect spinal cord or nerve compression and soft tissue masses, and whole-body MRI (or MRI of the spine and pelvis if whole-body MRI is not available) is recommended for the workup of solitary bone plasmacytoma. 38, 89 If MRI is unavailable, 18F-FDG PET/CT can be used in its place. 38 As per the IMWG criteria, patients presenting with > 1 focal lesion with a diameter ≥ 5 mm should be considered to have symptomatic disease that requires therapy. 6, 89 In cases of equivocal small lesions, a second MRI should be performed in 3 to 6 months. If progression is noted on the second MRI, the patient should be treated for MM.
Although conventional spin-echo T1-and T2-weighted MRI sequences provide sensitive assessment of bone marrow morphology, the addition of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging (DWI-MRI) can provide additional functional information on tumour-driven angiogenesis and cellularity, respectively. Including functional imaging not only improves sensitivity, but may be useful for response assessment following therapy. 92 DWI-MRI, unlike DCE-MRI, does not require contrast and is the functional modality included in the Myeloma Response Assessment and Diagnosis System core clinical protocol for whole-body MRI in myeloma. 93 A systematic review that included 6 studies (published from 2008 to 2016) and 147 patients suggested that wholebody MRI may be more sensitive than 18F-FDG PET/CT (68%-100% vs. 47%-100%, respectively), but less specific (37%-83% vs. 62%-85.7%, respectively); however, studies have not yet assessed its impact on initial management. 94 A major strength of 18F-FDG PET/CT is its ability to distinguish between metabolically active and inactive sites of disease. 95 A key limitation is low sensitivity for detection of small lytic lesions. 56 Several studies have shown that 18F-FDG PET/CT can have prognostic value. The number of 18F-FDG avid bone lesions, the intensity of uptake based on maximum standardized uptake value (SUV max ), and the presence of extramedullary disease have been shown to predict survival. [96] [97] Like whole-body MRI, 18F-FDG PET/CT provides functional imaging and is sensitive for bone marrow involvement. The IMWG recommends 18F-FDG PET/CT for newly diagnosed solitary extramedullary plasmacytoma. 38 The IMWG 2017 consensus guideline 98 recommends 18F-FDG-PET/CT as an option for: 1) suspected solitary plasmacytoma or SMM; 2) in cases where skeletal survey is negative and MRI is unable to be performed; and 3) to monitor effect of therapy on MM-cell metabolism. British Hematology Guidelines for the use of imaging in the management of MM patients indicates that 18F-FDG PET/CT is superior to skeletal survey and recommends that it be considered in asymptomatic patients with either 10% to 60% PC on a trephine biopsy or bone marrow aspirate or in patients with an M-protein > 30 g/L. 56 The diagnosis of MM has traditionally required evidence of end-organ damage attributable to the neoplastic clone of PCs: hypercalcemia, renal failure, anemia and osteolytic bone lesions, commonly referred to as CRAB criteria. 98 Although the criteria clearly distinguish MM patients, they do not identify those with true early stage malignant disease previously considered to be within the SMM subgroup. Thus, in 2014, the IMWG updated their diagnostic criteria for MM and SMM (Table 2 ) with the identification of reliable biomarkers that can accurately differentiate patients with high-risk SMM that are at risk of end-organ damage within a short timeframe. 6 It is also important to note that the criteria for renal failure includes creatinine clearance, allowing for better identification of kidney dysfunction in smaller and older patients, particularly elderly women. In addition, the kidney-related criteria have been updated to only include renal failure caused by light chain cast nephropathy as an MM-defining event. Although other forms of renal damage can occur in MM, they are not characteristic of MM and can be seen in other PC neoplasms or lymphoproliferative disorders.
Based on nephrologic evaluation, cast nephropathy can be proven by biopsy or deemed highly suspicious by other reasonable biochemical tests (ie, the presence of high involved FLC levels, typically > 1500 mg/L in the absence of significant albuminuria and other risk factors for renal failure). This highlights the importance of assessing the underlying causes of renal failure in PC neoplasms in order to recognize AL amyloidosis and other disorders.
According to the updated IMWG criteria, patients with a clonal BMPC burden ≥ 60% are defined as having active MM, regardless of the presence of CRAB features. 6 Furthermore, an involved:uninvolved sFLCr of ≥ 100 is a predictor of imminent progression to MM (from SMM), provided the involved sFLC is 100 mg/L or higher. As such, patients should be regarded as having MM requiring therapy. This recommendation is based on several studies that noted that the majority of patients (60% to 80%) with SMM and an involved:uninvolved sFLCr of ≥ 100 progress to MM or related disorders within 2 years. [99] [100] [101] This recommendation, however, is not applicable to patients with MGUS.
MM-related bone disease has been traditionally identified on the basis of conventional skeletal radiography. The updated IMWG criteria include more sensitive imaging modalities (ie, WBLDCT, MRI, and 18F-FDG-PET/CT) for detection of bone lesions. According to these criteria, CT and MRI are equally sensitive; therefore, either test can be used, depending on availability and access. 6, 102 However, as pointed out by the IMWG criteria, 6 increased metabolic uptake on PET without a detected lesion on CT is not adequate for the diagnosis of MM, and evidence of underlying osteolytic bone destruction is needed on the CT portion of the examination.
Lastly, the updated IMWG diagnostic criteria require focal lesions on MRI to be ≥ 5 mm in size. This is based on the observation that the presence of more than one focal lesion ≥ 5 mm was associated with a substantial increase in risk of progression (HR: 4.05, p < 0.001). 102 Thus, according to IMWG criteria, in patients with a solitary focal lesion, lesions < 5 mm, equivocal findings or diffuse marrow infiltration, follow-up examination in 3 to 6 months is recommended to enable an early and accurate diagnosis of MM. Although a diffuse marrow infiltration pattern in SMM is associated with increased risk of progression, it is not adequate for MM diagnosis. In cases of doubt, the 2014 IMWG criteria recommend considering bone lesion biopsy.
Consensus Recommendations: Management of Special Cases
We recommend the following in special cases of: 
C O N C L U S I O N
The recent and rapid advances in the treatment and management of MM and other PC disorders has led the MCRN-CGC to develop a set of recommendations specific to the investigation of these diseases. The availability of more precise and specific diagnostic tests requires careful consideration for the integration of these tests into the routine diagnostic armamentarium.
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Definition of MM
Clonal BMPCs ≥ 10%* or biopsy-proven bony or extramedullary plasmacytoma** and any one or more of the following MDEs:
• Evidence of end organ damage that can be attributed to the underlying PC proliferative disorder, specifically:
-Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL) -Renal insufficiency: creaƟnine clearance < 40 mL/min † or serum creaƟnine > 177 μmol/L (> 2 mg/dL) -Anemia: hemoglobin > 20 g/L below the lower limit of normal, or a hemoglobin concentration < 100 g/L -Bone lesion(s): ≥ 1 osteolytic lesion on skeletal radiography, CT, or 18F-PET/CT ‡ • Any one or more of the following biomarkers of malignancy:
-Clonal BMPCs ≥ 60%** -Involved:uninvolved sFLCr § ≥ 100 -> 1 focal lesions (each 5 mm or more in size) on MRI
Definition of SMM
Both criteria must be met: Clonal BMPCs ≥ 10% and any one or more of the following: 84 Adapted from Nat Rev Clin Oncol. 2018;15 (7):409-421, with permission from Springer Nature. * Each secondary cytogenetic abnormality alone or in combination can occur in any primary molecular MM subtype. 
Molecular Classification of MM on the Basis of Primary Cytogenetic Aberrations
